TriangleNCT03106779 · OUTCOME
Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the first dose of treatment up to study completion, up to 5 years
What was measured
Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.
Analysis population: The Full Analysis Set (FAS) comprised of all randomized participants. According to the intent to treat principle, participants were analyzed according to the treatment and stratum were assigned at randomization.
Groups in this outcome
Asciminib
Participants randomized to asciminib 40mg BID
Bosutinib
Participants randomized to bosutinib 500mg QD
| Group | Source count |
|---|---|
| Asciminib | 157 |
| Bosutinib | 76 |
Reported measurements
1 year
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Asciminib | 95.6 | Not reported | 90.4 | 98.0 | Not reported |
| Bosutinib | 91.4 | Not reported | 80.2 | 96.4 | Not reported |
3 years
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Asciminib | 85.7 | Not reported | 77.5 | 91.0 | Not reported |
| Bosutinib | 84.9 | Not reported | 69.6 | 92.9 | Not reported |
5 years
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Asciminib | 68.5 | Not reported | 47.2 | 82.7 | Not reported |
| Bosutinib | 64.6 | Not reported | 38.4 | 81.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 90.4
- upper Limit
- 98.0
- value
- 95.6
- group Id
- OG001
- lower Limit
- 80.2
- upper Limit
- 96.4
- value
- 91.4
- title
- 1 year
- categories
- measurements
- group Id
- OG000
- lower Limit
- 77.5
- upper Limit
- 91.0
- value
- 85.7
- group Id
- OG001
- lower Limit
- 69.6
- upper Limit
- 92.9
- value
- 84.9
- title
- 3 years
- categories
- measurements
- group Id
- OG000
- lower Limit
- 47.2
- upper Limit
- 82.7
- value
- 68.5
- group Id
- OG001
- lower Limit
- 38.4
- upper Limit
- 81.9
- value
- 64.6
- title
- 5 years
- denoms
- counts
- group Id
- OG000
- value
- 157
- group Id
- OG001
- value
- 76
- units
- Participants
- description
- Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants randomized to asciminib 40mg BID
- id
- OG000
- title
- Asciminib
- description
- Participants randomized to bosutinib 500mg QD
- id
- OG001
- title
- Bosutinib
- param Type
- NUMBER
- population Description
- The Full Analysis Set (FAS) comprised of all randomized participants. According to the intent to treat principle, participants were analyzed according to the treatment and stratum were assigned at randomization.
- reporting Status
- POSTED
- time Frame
- From the first dose of treatment up to study completion, up to 5 years
- title
- Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice